Allecra Therapeutics secures EUR22m Series B financing
Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, has closed a EUR22 million Series B investment round. The round was led by new investor, Delos Capital. Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures and Allecra's co-Founder